评估微卫星改变（MSA）作为乳腺癌血清标志物：与癌胚抗原（CEA）的比较。
Evaluation of MSA as a serum marker in breast cancer: a comparison with CEA.
作者信息
Stacker S A, Sacks N P, Golder J, Tjandra J J, Thompson C H, Smithyman A, McKenzie I F
机构信息
Department of Pathology, University of Melbourne, Parkville, Vic., Australia.
出版信息
Br J Cancer. 1988 Mar;57(3):298-303. doi: 10.1038/bjc.1988.66.
In a blind study, 518 serum samples were assayed for serum levels of mammary serum antigen (MSA) by an enzyme immunoassay (EIA) using the 3E1.2 monoclonal antibody. Using 300 IU as the arbitrary cut off to distinguish normal from abnormal individuals, 75% of patients with primary Stage I carcinoma of the breast (n = 12), 89% of those with Stage II (n = 9) and 93% of those with Stage IV (n = 57) had elevated levels of MSA. A relationship was observed between the level of MSA and stage of disease, and therefore with the extent of tumour burden. Levels of MSA were also determined in a series of 19 patients undergoing chemotherapy for breast cancer. Over a 2-24 month period, the change of MSA levels corresponded with the clinical course of the disease in 17 (89%) cases. MSA levels were also raised in some patients with ovarian, colon, lung and kidney cancer, but the average level was lower than in patients with breast cancer. A comparison of CEA and MSA levels in these patients revealed that MSA was a substantially better marker for breast cancer than CEA. The results of this study demonstrate that MSA levels are elevated in patients with breast cancer and may provide a useful means of following the clinical course of patients with this disease.
在一项盲法研究中，使用3E1.2单克隆抗体通过酶免疫测定法（EIA）对518份血清样本进行乳腺血清抗原（MSA）血清水平检测。以300 IU作为区分正常人与异常个体的任意临界值，原发性I期乳腺癌患者（n = 12）中有75%、II期患者（n = 9）中有89%以及IV期患者（n = 57）中有93%的MSA水平升高。观察到MSA水平与疾病分期之间存在关联，因此也与肿瘤负荷程度相关。还对19例接受乳腺癌化疗的患者进行了MSA水平测定。在2至24个月的期间内，17例（89%）患者的MSA水平变化与疾病临床进程相符。一些卵巢癌、结肠癌、肺癌和肾癌患者的MSA水平也有所升高，但平均水平低于乳腺癌患者。对这些患者的癌胚抗原（CEA）和MSA水平进行比较发现，对于乳腺癌而言，MSA是比CEA更好的标志物。本研究结果表明，乳腺癌患者的MSA水平升高，可能为跟踪该疾病患者临床进程提供一种有用的方法。
Zotero 插件